Zimmer: FDA clears knee surgery guidance system

WARSAW, Ind. -- Zimmer Holdings Inc. said Thursday the Food and Drug Administration cleared a new guidance system designed for use in knee replacement surgeries.

The company said its iAssist Knee system uses small, disposable electronic components at the site of the surgery and a simple electronic display. Zimmer said the system does not require pins or additional surgical incisions, and no external monitoring systems are needed.

Zimmer said other guidance systems require complex and bulky additional equipment, external computer screens, and a clear line of sight into the surgical area.

Shares of Zimmer rose $1.09 to $73 on Thursday and picked up 13 cents to $73.13 in aftermarket trading.

View the original article here

FDA clears study of Neuralstem spinal cord therapy

  Published: Monday, 14 Jan 2013 | 4:34 PM ET

NEW YORK -- Adult stem cell developer Neuralstem Inc. said Monday the Food and Drug Administration approved the company's plan for a small, early-stage study of its treatment for spinal cord injury.

The company plans to enroll up to eight patients with a type of spinal cord injury that causes complete paralysis.

All patients in the study will receive six injections of stem cells, followed by physical therapy and drugs to prevent the body from rejecting the stem cells.

Neuralstem is studying several therapeutic uses of adult stem cells. The company completed phase I testing of a treatment for Lou Gehrig's disease in August.

Shares of Neuralstem Inc. rose 5 cents, or 4 percent, to close at $1.29.

.

NEW YORK-- Adult stem cell developer Neuralstem Inc. said Monday the Food and Drug Administration approved the company's plan for a small, early-stage study of its treatment for spinal cord injury. Neuralstem is studying several therapeutic uses of adult stem cells. Shares of Neuralstem Inc. rose 5 cents, or 4 percent, to close at $1.29.

View the original article here

FDA clears anticlotting drug Eliquis

WASHINGTON -- The Food and Drug Administration said Friday that it approved an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster in a new category of medicines to prevent strokes.

The agency previously rejected the drug twice, most recently in June, awaiting additional data from company trials.

The FDA cleared the pill for treating the most common type of irregular heartbeat, atrial fibrillation, in patients at risk for strokes or dangerous clots.

About a quarter of all people aged 40 and older develop atrial fibrillation, a condition in which the heart's two upper chambers contract irregularly and don't pump blood efficiently. This can persist for years or only happen occasionally. The condition increases the risk of a stroke fivefold.

For decades atrial fibrillation patients were treated with the blood thinner warfarin, sold under brands that included Coumadin. While warfarin is cheap, users must get frequent blood tests to ensure they're getting enough to prevent strokes but not too high a dose, which can cause dangerous internal bleeding.

In the last two years drug regulators in the U.S. and other countries have approved two other new anticlotting drugs for patients with atrial fibrillation: Pradaxa, from German drugmaker Boehringer Ingelheim, and Xarelto from partners Johnson & Johnson and Bayer Healthcare.

Some analysts have said Eliquis, known chemically as apixaban, is the best of the three new drugs, but Pradaxa and Xarelto got a big head start in building U.S. market share. That means that Pfizer and Bristol-Myers could have a tough job persuading doctors and patients who already have switched from warfarin to Pradaxa or Xarelto to again switch medication.

Eliquis is manufactured by Bristol-Myers Squibb and co-marketed with Pfizer. Both companies are based in New York.

The FDA said it approved the drug based on an 18,000-patient study conducted by the drugmakers. The trial showed that patients taking Eliquis had fewer strokes than those taking warfarin.

The agency warned that patients with artificial heart valves should not take the drug because it was not studied in that population.

In after-hours trading Bristol-Myers rose 60 cents to $32.50. Pfizer picked up 13 cents at $25.02.

View the original article here